# A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

> **NCT06136988** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 129 (estimated)

## Conditions studied

- Locally Advanced Unresectable Esophageal Squamous Carcinoma

## Interventions

- **DRUG:** Docetaxel for Injection (Albumin-bound)
- **DRUG:** SG001
- **DRUG:** Cisplatin for injection
- **DRUG:** Paclitaxel
- **RADIATION:** Simultaneous Radiotherapy

## Key facts

- **NCT ID:** NCT06136988
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 129 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06136988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06136988, "A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06136988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*